度伐利尤单抗在局限期小细胞肺癌治疗中的研究进展 点击下载
| 论文标题: | 度伐利尤单抗在局限期小细胞肺癌治疗中的研究进展 |
| 英文标题: | |
| 中文摘要: | 度伐利尤单抗巩固治疗可延长同步放化疗后未进展的局限期小细胞肺癌患者的生存期,其临床应用涉及治疗衔接、肺部不良事件及长期用药管理。本文综述该药的疗效与安全性、治疗模式与介入时机、用药管理、疗效预测与治疗优化、药物经济学与临床可及性,发现现有随机研究支持在同步放化疗结束后采用度伐利尤单抗巩固治疗;在同步放化疗期间加入度伐利尤单抗,或将其用于围手术期治疗的证据仍较有限,目前尚不能证明这些方案优于放化疗后巩固治疗。用药期间应重点鉴别免疫相关肺炎、放射性肺炎及感染,并根据受累器官和严重程度处理不良事件。度伐利尤单抗在生物标志物、联合曲美木单抗及缩短疗程方面的价值仍待验证。其药物经济学研究的分歧主要涉及药品价格、模型参数及长期生存外推,需结合具体支付环境进行解读。 |
| 英文摘要: | Durvalumab consolidation therapy can prolong survival in patients with limited-stage small-cell lung cancer (LS-SCLC) who have not progressed after concurrent chemoradiotherapy. Its clinical application involves treatment sequencing, monitoring for pulmonary adverse events, and long-term follow-up medication management. This article reviews the efficacy and safety of durvalumab, treatment modalities and timing, medication management, predictive biomarkers and treatment optimization, pharmacoeconomics, and clinical accessibility. Available randomized data support durvalumab consolidation after concurrent chemoradiotherapy. Evidence for adding durvalumab during concurrent chemoradiotherapy or administering it in the perioperative setting remains limited, and these regimens have not been shown to be superior to post-chemoradiotherapy consolidation therapy. During treatment, clinicians should prioritize differentiating immune-related pneumonitis, radiation pneumonitis, and infection, and manage adverse events according to the involved organ and severity. The value of biomarkers, combination therapy with tremelimumab, and shortened treatment duration requires further validation. Discrepancies across pharmacoeconomic studies mainly involve drug pricing, model parameters, and long-term survival extrapolation; such findings should be interpreted in light of the specific payment environment. |
| 期刊: | 2026年第37卷第21期 |
| 作者: | 周玉华;沈洁华;王飞 |
| 英文作者: | ZHOU Yuhua,SHEN Jiehua,WANG Fei |
| 关键字: | 度伐利尤单抗;局限期小细胞肺癌;巩固治疗;免疫治疗时机;药学监护;药物经济学 |
| KEYWORDS: | limited-stage small-cell lung cancer;consolidation therapy;immunotherapy timing;pharmaceutical care;pharmacoeconomics |
| 总下载数: | 81次 |
| 本日下载数: | 2次 |
| 本月下载数: | 81次 |
| 文件大小: | 619.60Kb |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!